Unmasking Multiple Myeloma and Its Precursor Conditions in Primary Care

Jointly provided by

     

This activity is supported by educational grants from AbbVie Inc.; Karyopharm Therapeutics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and The Binding Site, part of Thermo Fisher Scientific.

Release date: 3/15/2024

Expiration date: 3/15/2025

Estimated time to complete: 0.5 hours

Overview

For multiple myeloma (MM) patients to receive the most appropriate care, a quick and accurate diagnosis is paramount. This is especially the case for Black patients, as diagnosis has historically been slower in Black patients—even though MM is twice as common in Black Americans than in White Americans. Additionally, MM precursor conditions such as monoclonal gammopathy of undetermined significance are seen more frequently in Black Americans than in White Americans. Primary care providers (PCPs) are in the best position to identify patients with MM or its precursor conditions, but diagnosing these conditions is challenging, as the signs and symptoms of MM and its precursor conditions are variable, often nonspecific, and overlap with many other health conditions.

Faculty

Hearn Jay Cho, MD, PhD
Chief Medical Officer
Multiple Myeloma Research Foundation
Norwalk, Connecticut
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Yvens G. Laborde, MD
Chief Community Medical Officer
Adjunct Associate Professor of Medicine
University of Queensland Ochsner Clinical School of Ochsner Health
New Orleans, Louisiana

Target Audience

This activity will be designed to meet the educational needs of PCPs involved in the care of patients who have or are at risk of developing MM.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize the clinical presentations that should raise suspicion of MM and its precursor conditions
  • Identify optimal diagnostic testing to minimize delays in diagnosis
  • Increase and/or speed referrals to MM specialists

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC)  
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 ABIM MOC Part 2 credit MOC point in the ABIM’s MOC program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Additional information will be collected from participants claiming MOC credit, including their ABIM registration number and birth date (mm/dd). MOC participant data will be uploaded to the ACCME PARS system by Penn State College of Medicine, which will automatically transmit the data to ABIM.

Disclosure

In accordance with the ACCME Standards for Integrity and Independence, all CE providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 24 months with an ineligible company whose products or services are discussed in the CE activity content over which the individual has control.

All of the relevant financial relationships listed for these individuals have been mitigated. Relationship information appears below:

Hearn Jay Cho, MD, PhD, discloses the following:
Research grant: BMS, Roche, Takeda

Yvens G. Laborde, MD, has no relevant financial information to disclose.

Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

RedMedEd
The RedMedEd planners have disclosed no relevant financial relationships.

The Multiple Myeloma Research Foundation
The MMRF planners have disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Multiple Myeloma Research Foundation, Penn State College of Medicine, RedMedEd, AbbVie, Karyopharm, Pfizer, Regeneron, and The Binding Site, part of Thermo Fisher Scientific, do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the Multiple Myeloma Research Foundation, Penn State College of Medicine, RedMedEd, AbbVie, Karyopharm, Pfizer, Regeneron, or The Binding Site, part of Thermo Fisher Scientific. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content.

To receive CME credit, participants must complete the posttest and program evaluation. Participants must score at least 75% on the posttest. Certificates can be printed immediately.

For  ABIM MOC credit, Penn State College of Medicine will submit participant completion information to the ACCME; credit will be granted within 6–8 weeks.

Contact Information

For questions regarding CME credit, contact Penn State Continuing Education at 717.531.6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G7012-24-T.

For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.

Hardware/Software Requirements

  • iPad, iPad Mini (iPadOS 15 or higher), iPhone (iOS 15 or higher), or Android device (OS 11 or higher) with an Internet connection
    • Internet browsers: Chrome, Firefox, Safari
  • A computer with an Internet connection
    • Internet browsers (PC): Chrome, Firefox, Microsoft Edge
    • Internet browsers (Mac): Chrome, Firefox, Safari

Privacy

CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine or RedMedEd. For more information, contact Penn State Continuing Education at ContinuingEd@hmc.psu.edu or RedMedEd at education@redmeded.com.

Copyright

© 2024. This CME-certified program is held as copyrighted by Penn State College of Medicine, The Multiple Myeloma Research Foundation, and RedMedEd. Through this notice, the Penn State College of Medicine, The Multiple Myeloma Research Foundation, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.